Barrier Proteins in Tumors are Possible Key to Immunotherapy SuccessEurekAlert (press release)By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute a… Continue reading
Telegraph.co.uk |
GM purple rice could cut risk of cancer
Telegraph.co.uk “Our research provides a high-efficiency vector system for stacking multiple genes for synthetic biology and makes it potentially feasible for engineering complex biosynthesis pathways in the endosperm of rice and other crop plants such as maize, wheat … |
Telegraph.co.uk |
GM purple rice could cut risk of cancer
Telegraph.co.uk “Our research provides a high-efficiency vector system for stacking multiple genes for synthetic biology and makes it potentially feasible for engineering complex biosynthesis pathways in the endosperm of rice and other crop plants such as maize, wheat … |
|
First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine …
Markets Insider Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today the first administration in the Phase I clinical study in Acute … |
Seeking Alpha |
Buy Celyad And Get In On The CAR–T Space In Solid Tumors: Medicine’s Next Frontier
Seeking Alpha In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor – T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T–cells that express a specific tumor antigen … |